Miao L, Liu C, Cheong MS, Zhong R, Tan Y, Rengasamy KRR, Leung SWS, Cheang WS, Xiao J (2022) Exploration of natural flavones’ bioactivity and bioavailability in chronic inflammation-induced type 2 diabetes mellitus. Crit Rev Food Sci Nutr 63(33):11640–11667. https://doi.org/10.1080/10408398.2022.2095349

Article  PubMed  CAS  Google Scholar 

Gassasse Z, Smith D, Finer S, Gallo V (2017) Association between urbanisation and type 2 diabetes: an ecological study. BMJ Glob Health 2(4):e000473. https://doi.org/10.1136/bmjgh-2017-000473

Article  PubMed  PubMed Central  Google Scholar 

Preethi KA, Selvakumar SC, Sekar D (2022) Diagnostic and therapeutic application of exosomal microRNAs inducing inflammation in type 2 diabetes mellitus. Crit Rev Immunol 42(1):1–11. https://doi.org/10.1615/critrevimmunol.2022044927

Article  PubMed  Google Scholar 

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843

Article  PubMed  Google Scholar 

MI, Kumar SL, Eswaramoorthy R, Kumar Vadivel J, Prethipa R (2024) Evaluation of salivary butylated hydroxytoluene and ascorbic acid levels in type 2 diabetes mellitus patients. Cureus 16(3):e56590. https://doi.org/10.7759/cureus.56590

Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW et al (2018) IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281. https://doi.org/10.1016/j.diabres.2018.02.023

Article  PubMed  CAS  Google Scholar 

Deborah WJ (n.d.) Patient education: type 2 diabetes: insulin treatment (Beyond the Basics). UpToDate. https://www.uptodate.com/contents/type-2-diabetes-insulin-treatment-beyond-the-basics/print. Accessed 11 Apr 2025

Majety P, Lozada Orquera FA, Edem D, Hamdy O (2023) Pharmacological approaches to the prevention of type 2 diabetes mellitus. Front Endocrinol (Lausanne) 14:1118848. https://doi.org/10.3389/fendo.2023.1118848

Article  PubMed  Google Scholar 

Rachdaoui N (2020) Insulin: the friend and the foe in the development of type 2 diabetes mellitus. Int J Mol Sci 21(5):1770. https://doi.org/10.3390/ijms21051770

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lamb YN (2021) Imeglimin hydrochloride: first approval. Drugs 81(14):1683–1690. https://doi.org/10.1007/s40265-021-01589-9

Article  PubMed  CAS  Google Scholar 

Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H (2022) Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab 24(5):838–848. https://doi.org/10.1111/dom.14661

Article  PubMed  PubMed Central  CAS  Google Scholar 

Clémence C, Fouqueray P, Sébastien B (2020) In vitro investigation, pharmacokinetics, and disposition of imeglimin, a novel oral antidiabetic drug, in preclinical species and humans. Drug Metab Dispos 48(12):1330–1346. https://doi.org/10.1124/dmd.120.000156

Article  PubMed  CAS  Google Scholar 

Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27:740–756. https://doi.org/10.1016/j.cmet.2018.03.001

Article  PubMed  CAS  Google Scholar 

Hallakou-Bozec S, Kergoat M, Fouqueray P, Bolze S, Moller DE (2021) Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS ONE 16(2):e0241651. https://doi.org/10.1371/journal.pone.0241651

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pacini G, Mari A, Fouqueray P, Bolze S, Roden M (2015) Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 17(6):541–545. https://doi.org/10.1111/dom.12459

Article  PubMed  CAS  Google Scholar 

Katsyuba E, Mottis A, Zietak M et al (2018) De novo NAD+ synthesis enhances mitochondrial function and improves health. Nature 563(7731):354–359. https://doi.org/10.1038/s41586-018-0645-6

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fouqueray P, Leverve X, Fontaine E et al (2011) Imeglimin – a new oral antidiabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab 2(4):126. https://doi.org/10.4172/2155-6156.1000126

Article  Google Scholar 

Perry RJ, Cardone RL, Petersen MC et al (2016) Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab 311:E461–E470. https://doi.org/10.1152/ajpendo.00009.2016

Article  PubMed  PubMed Central  Google Scholar 

Vial G, Chauvin MA, Bendridi N et al (2015) Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 64:2254–2264. https://doi.org/10.2337/db14-1220

Article  PubMed  CAS  Google Scholar 

Hallakou-Bozec S, Kergoat M, Fouqueray P, Bolze S, Moller DE (2020) Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS ONE 16(2):e0241651. https://doi.org/10.1371/journal.pone.0241651

Article  CAS  Google Scholar 

Li J, Shirakawa J, Togashi Y, Terauchi Y (2019) 2130-P: imeglimin modulated ER stress to prevent SS-cell apoptosis induced by high glucose or thapsigargin. Diabetes 68(Supplement_1):2130-P

Detaille D, Vial G, Borel AL et al (2016) Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov 2:15072. https://doi.org/10.1038/cddiscovery.2015.72

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vial G, Lamarche F, Cottet-Rousselle C, Hallakou-Bozec S, Borel A, Fontaine E (2021) The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Endocrinol Diabetes Metab 4(2). https://doi.org/10.1002/edm2.211

Li Y, Lou N, Liu X, Zhuang X, Chen S (2024) Exploring new mechanisms of imeglimin in diabetes treatment: amelioration of mitochondrial dysfunction. Biomed Pharmacother 175:116755. https://doi.org/10.1016/j.biopha.2024.116755

Article  PubMed  CAS  Google Scholar 

Wagner F, Vogt J, Wachter U, Weber S, Stahl B, Groeger M, McCook O, Georgieff M, Fouqueray P, Kuhn T, Calzia E, Radermacher P, Fontaine E, Wagner K (2012) Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock. Crit Care 16(S1):P21. https://doi.org/10.1186/cc10628

Article  PubMed Central  Google Scholar 

Yaribeygi H, Maleki M, Sathyapalan T, Iranpanah H, Orafai HM, Jamialahmadi T, Sahebkar A (2020) The molecular mechanisms by which vitamin D improve glucose homeostasis: a mechanistic review. Life Sci 244:117305. https://doi.org/10.1016/j.lfs.2020.117305

Article  PubMed  CAS  Google Scholar 

Pirags V, Lebovitz H, Fouqueray P (2012) Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 14(9):852–858. https://doi.org/10.1111/j.1463-1326.2012.01612.x

Article  PubMed  CAS  Google Scholar 

Konkwo C, Perry RJ (2020) Imeglimin: current development and future potential in type 2 diabetes. Drugs 81(2):185–190. https://doi.org/10.1007/s40265-020-01434-5

Article  CAS  Google Scholar 

Eguchi N, Vaziri ND, Dafoe DC, Ichii H (2021) The role of oxidative stress in pancreatic β cell dysfunction in diabetes. Int J Mol Sci 22(4):1509. https://doi.org/10.3390/ijms22041509

Article  PubMed  PubMed Central  CAS  Google Scholar 

Canto C, Menzies KJ, Auwerx J (2015) NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab 22(1):31–53. https://doi.org/10.1016/j.cmet.2015.05.023

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hallakou-Bozec S, Kergoat M, Fouqueray P, Bolze S, Moller DE (2021) Mechanism of action of imeglimin: a novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab 23(3):664–673. https://doi.org/10.1111/dom.14249